A Study Of Cnty-101 In Participants With Cd19-Positive B-Cell Malignancies (Elipse-1)
Posted Date: Apr 25, 2024
- Investigator: Tahir Latif
- Specialties:
- Type of Study: Drug
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies
Criteria:
Null
Keywords:
Non-Hodgkin Lymphoma, B-Cell Malignancies
For More Information:
Emily Greve
NULL
cancer@uchealth.com